Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
Retatrutide
Metabolic & Weight Loss
Molecular Dossier
- Rank Index: 3
- Status: Phase 3 Clinical
- What does this mean?
- Molecular Structure: Synthetic Peptide (C221H342N62O71S)
About Retatrutide
Retatrutide (LY3437943, "tirzepatide on steroids") is Eli Lilly's next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Once-weekly subcutaneous injection. Phase 3 TRIUMPH trials reported results in early 2026: TRIUMPH-1 and TRIUMPH-2 obesity trials showed up to 28.7% average body weight reduction at 48 weeks (significantly outperforming both semaglutide ~14.9% and tirzepatide ~22% at highest doses). TRIUMPH-4 (obesity + knee osteoarthritis) showed not only 28.7% weight loss but also pain reduction up to 75.8% on the WOMAC pain scale — suggesting glucagon receptor activation may provide joint-specific analgesic benefit independent of weight loss. The triple mechanism is distinctive: GLP-1R drives satiety and insulin secretion; GIPr amplifies these signals; GcgR activation increases hepatic glucose production, thermogenesis, and fat oxidation — creating a potent synergistic weight loss profile. Phase 3 MASH trials are planned. Retatrutide regulatory submission to the FDA is expected in 2026, with potential approval in 2026–2027. Gastrointestinal adverse events are dose-dependent, with nausea more common than semaglutide/tirzepatide at equipotent doses. The compound is currently available only through clinical trial enrollment. Post-marketing surveillance will focus on pancreatitis, cardiovascular outcomes, and long-term tolerability.
Clinical Focus
Triple Agonist Weight Loss
Archival Aliases
Triple G, Reta, The 3-G Agonist
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
What is the mechanism of Retatrutide’s triple-agonism?
Retatrutide activates GLP-1, GIP, and Glucagon receptors. While GLP-1 and GIP suppress appetite and improve insulin sensitivity, the Glucagon component increases energy expenditure and lipid catabolism in the liver. This "thermostat" effect is why Retatrutide shows higher efficacy in visceral fat reduction compared to mono-agonists.
What makes retatrutide a triple agonist?
Retatrutide (LY3437943) is the first triple co-agonist to reach Phase 3 clinical trials. It simultaneously activates three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and the glucagon receptor. GIP and GLP-1 suppress appetite and improve insulin sensitivity. Glucagon agonism increases hepatic fat metabolism and energy expenditure. The combination produces weight loss superior to dual GIP/GLP-1 agonists like tirzepatide.
What weight loss results have Phase 2 retatrutide trials shown?
The Phase 2 dose-finding trial (NEJM, 2023) reported 24-week results of up to 17.5% body weight reduction at the highest dose studied (12mg weekly). Participants who completed 48 weeks of treatment achieved up to 24.2% mean weight reduction — a figure that exceeds any previously approved obesity medication and approaches outcomes seen with bariatric surgery.
How does retatrutide differ from tirzepatide?
Tirzepatide (Mounjaro/Zepbound) is a GIP/GLP-1 dual agonist that achieves approximately 20-22% weight loss in clinical trials. Retatrutide adds glucagon receptor agonism, which further increases energy expenditure through hepatic fat burning and thermogenic activity. Early head-to-head comparisons suggest retatrutide produces greater total weight loss, particularly in reducing liver fat in NASH/MASLD patients.
What are the side effects of retatrutide?
The side effect profile is similar to other GLP-1 class drugs but amplified. In Phase 2 trials, nausea affected 45-57% of participants, diarrhea 28-40%, and vomiting 19-29%. Injection site reactions occurred in ~24%. Gallbladder events (cholelithiasis) were observed. The glucagon component may also increase heart rate, which is being monitored in Phase 3 cardiovascular safety trials.
What is the current regulatory status of retatrutide?
As of April 2026, Eli Lilly's retatrutide (SURMOUNT-5 and TREASURE program) is in Phase 3 clinical trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). It has not received FDA approval. Regulatory submission for obesity is anticipated pending trial completion and review, potentially in 2027.
Can retatrutide treat liver disease?
Yes — this is one of retatrutide's most distinctive differentiation points. The glucagon receptor component makes it particularly effective for non-alcoholic and metabolic fatty liver disease. Clinical trial data shows significant reductions in liver fat fraction and liver enzyme levels (ALT, AST). It is being studied specifically in MASH (Metabolic Dysfunction-Associated Steatohepatitis) patients where no approved systemic treatment currently exists.
Does the glucagon component of retatrutide cause blood sugar increases?
Glucagon is classically known as a counter-regulatory hormone that raises blood glucose. However, in the context of retatrutide, the simultaneous GLP-1 and GIP receptor activation provides potent insulin-stimulating and glucose-lowering activity that offsets the glucagon effect. Clinical data shows net improvements in HbA1c and fasting glucose across diabetic and non-diabetic populations, suggesting the multi-receptor balance is well-calibrated.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | Synthetic Peptide (C221H342N62O71S) |
| Primary Pathway | Metabolic & Weight Loss |
| Research Phase | Phase 3 Clinical |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-07